PANOBINOSTAT LACTATE bulk active fine chemical suppliers

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
ChemShuttle	⤷ Start Trial	139065	⤷ Start Trial
iChemical Technology USA Inc	⤷ Start Trial	EBD843626	⤷ Start Trial
BLD Pharm	⤷ Start Trial	BD566148	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 30, 2025

Introduction

The pharmaceutical landscape is increasingly shifting toward the sourcing of high-quality Active Pharmaceutical Ingredients (APIs) from global manufacturers to support the development and commercialization of new therapies. Panobinostat lactate, an HDAC inhibitor marketed under the brand name Farydak®, represents a critical therapeutic agent used primarily in oncology, notably multiple myeloma treatment. Ensuring reliable, high-quality supply chains for Panobinostat lactate API is vital for pharmaceutical companies, contract manufacturing organizations (CMOs), and research entities. This article provides a comprehensive overview of global sources for Panobinostat lactate API, with insights into manufacturing regions, supplier credentials, and key considerations for industry stakeholders.

Understanding Panobinostat Lactate and Its API Requirements

Panobinostat lactate is a synthetic small molecule that inhibits histone deacetylases (HDACs), modulating gene expression—a mechanism exploited in oncology and hematology. The synthesis of Panobinostat lactate requires sophisticated chemical processes emphasizing purity, stereochemistry, and stability. These parameters influence API sourcing decisions to guarantee compliance with international pharmacopeias (such as USP, EP), Good Manufacturing Practices (GMP), and regulatory approvals.

Global API Manufacturing Regions for Panobinostat Lactate

1. India

India remains a prominent hub for generic APIs, including complex molecules like Panobinostat lactate. Indian manufacturers often leverage advanced chemistries and robust regulatory compliance frameworks aligned with the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). Major Indian API producers include:

Biocon Ltd.: A pioneer in biologics and synthetic API manufacturing, with capacity for complex molecules.
Aurobindo Pharma: Known for a vast API portfolio, including oncology APIs.
Hetero Labs: Specializing in complex chemical synthesis and conforming to GMP standards.

Indian API producers often provide competitive pricing, accelerated lead times, and extensive quality validation, making India a preferred source for global pharmaceutical companies [1].

2. China

China's API manufacturing sector has expanded rapidly, driven by technological advances and increasing capacity for complex small molecules. Chinese suppliers are renowned for:

Cost-effective manufacturing solutions.
Extensive chemical synthesis capabilities suitable for APIs like Panobinostat lactate.
Integration with global supply chains.

Leading Chinese API manufacturers include:

Shanghai Fosun Pharmaceutical: With dedicated facilities for oncology APIs.
BBI Life sciences: Offering GMP-validated APIs with export capabilities.
Qingdao Sinopharm: Providing a wide array of pharmaceutical ingredients.

However, regulatory oversight and quality control are critical considerations when sourcing from Chinese suppliers, necessitating thorough audits and validation [2].

3. Europe

European API manufacturers focus on high purity, stringent regulatory compliance, and complex chemical synthesis suited for oncologic agents:

Evonik Industries: Known for specialty chemicals and pharmaceutical intermediates.
Siegfried AG: Offers high-quality APIs with extensive GMP certification.
BASF: Engaged in complex chemical processes, including oncology-related APIs.

European sources typically command higher price points but ensure compliance with strict regulatory standards. The region remains vital for APIs intended for markets with high regulatory stringency, including the US and EU [3].

4. United States

While the US hosts limited API manufacturing for complex oncologic agents like Panobinostat lactate, several Contract Manufacturing Organizations (CMOs) and China-based companies with USFDA-approved facilities provide API synthesis and supply:

Catalent and Lonza: Globally recognized CMOs with US and Switzerland facilities capable of producing high-quality APIs.
Fukuyama Reagents: Japanese company with specialized APIs production, including oncology molecules.

US-based manufacturing options, although fewer, emphasize regulatory compliance, supply security, and advanced quality control.

Key Factors in Selecting API Suppliers for Panobinostat Lactate

Regulatory Compliance & Quality Assurance

GMP certification according to FDA, EMA, or WHO standards.
Active validation records and thorough documentation.
Stability and purity profiles meeting pharmacopeial standards.

Manufacturing Capabilities & Capacity

Expertise in complex chemical synthesis, stereoselective reactions.
Scale-up capacity aligned with clinical trial and commercial demands.

Supply Chain Reliability

Proven track record of consistent delivery timelines.
Robust inventory management and contingency planning.

Cost and Lead Time

Competitive pricing strategies without compromising quality.
Flexibility in lead times for urgent requirements.

Documentation & Technical Support

Comprehensive quality documentation (Certificates of Analysis, Drug Master Files).
Responsive technical support for process troubleshooting and validation.

Current Trends and Strategic Considerations

Diversification of sourcing to mitigate supply chain risks associated with geopolitical uncertainties and regulatory hurdles.
Vertical integration seen in some large pharmaceutical firms developing in-house manufacturing capabilities for critical APIs like Panobinostat lactate.
Technological advancements in synthetic methodologies, including green chemistry, improving yields, and reducing impurities.
Regulatory harmonization efforts to facilitate faster approvals and easier cross-border supply chain management.

Conclusion

Globally, Indian and Chinese manufacturers dominate the bulk API supply landscape for Panobinostat lactate, owing to their extensive chemical expertise and cost-effective production capabilities. European and select US-based suppliers emphasize high regulatory standards and product purity, catering to markets with stringent compliance requirements. Strategic supplier selection hinges on compliance, capacity, and supply stability, underscoring the importance for stakeholders to conduct meticulous due diligence.

Key Takeaways

India and China are primary sources for Panobinostat lactate API, offering cost-effective large-scale production.
European and US suppliers prioritize high regulatory standards, suitable for compliance-sensitive markets.
Due diligence, including regulatory certification, quality validation, and supply reliability, is critical when selecting API sources.
Diversification of supply chains mitigates risks associated with geopolitical and regulatory challenges.
Innovation in chemical synthesis and quality assurance continues to shape the landscape of API sourcing for oncology agents.

FAQs

Q1. What are the main considerations when sourcing Panobinostat lactate API internationally?
Regulatory compliance, quality assurance, manufacturing capacity, supply reliability, and cost are paramount. Ensuring GMP certification and validated processes is essential.

Q2. How do Indian and Chinese API manufacturers compare in quality?
Both regions produce high-quality APIs, but Indian manufacturers tend to have more extensive GMP compliance efforts aligned with international standards, while Chinese suppliers offer cost advantages, requiring thorough validation.

Q3. Are there US-based manufacturers producing Panobinostat lactate API?
Limited US-based API manufacturers produce complex oncologic agents. Most US requirements rely on international suppliers with USFDA-approved facilities to ensure regulatory standards are met.

Q4. How does supply chain diversification benefit pharmaceutical companies?
It reduces dependence on a single source, mitigates geopolitical or regulatory disruptions, and enhances supply security for critical APIs like Panobinostat lactate.

Q5. What emerging trends impact Panobinostat lactate API sourcing?
Technological innovations in synthesis, green chemistry approaches, and regulatory harmonization are improving supply chain efficiency and quality management for complex APIs.

References

[1] World Health Organization. (2022). The Role of Indian Generic Pharma in Global Supply Chain. WHO Publications.

[2] U.S. Food & Drug Administration. (2021). Considerations for sourcing APIs from China and India.

[3] European Medicines Agency. (2022). Quality Standards in API Manufacturing.

This authoritative overview aims to inform strategic decision-making for pharmaceutical enterprises, emphasizing quality, compliance, and supply chain resilience in sourcing Panobinostat lactate API.

Bulk Pharmaceutical API Sources for panobinostat lactate